For research use only. Not for therapeutic Use.
L82 is a selective and uncompetitive DNA ligase 1 (DNA Lig1) inhibitor (hLig1 IC50=12 μM). L82 shows anti-proliferative activity to breast cancer cells[1][2].
L82 (0-50 μM; 6 d) shows anti-proliferative activity to breast cancer cells[2].
L82 (50 μM; 0-48 h) shows cytostatic activity due to activation of the G1/S checkpoint in MCF7 cells[2].
| Catalog Number | I042740 |
| CAS Number | 329227-30-7 |
| Synonyms | 5-chloro-4-[(2E)-2-[(4-hydroxy-3-nitrophenyl)methylidene]hydrazinyl]-1H-pyridazin-6-one |
| Molecular Formula | C11H8ClN5O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C11H8ClN5O4/c12-10-7(5-14-16-11(10)19)15-13-4-6-1-2-9(18)8(3-6)17(20)21/h1-5,18H,(H2,15,16,19)/b13-4+ |
| InChIKey | WUVOGTSGMTVCGA-YIXHJXPBSA-N |
| SMILES | C1=CC(=C(C=C1C=NNC2=C(C(=O)NN=C2)Cl)[N+](=O)[O-])O |
| Reference | [1]. Howes TRL, et al. Structure-activity relationships among DNA ligase inhibitors: Characterization of a selective uncompetitive DNA ligase I inhibitor. DNA Repair (Amst). 2017 Dec;60:29-39. [2]. Chen X, et al. Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res. 2008 May 1;68(9):3169-77. |
